Figure 2

Effect of gender on VAS score. The 98 patients receiving peripheral venous chemotherapy with or without oxaliplatin for CRC included 41 females and 57 males. There was no significant difference in VAS scores between males and females (Wilcoxon’s test, P = 0.767).